Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Axcella Health Inc. (AXLA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events ...
08/04/2023 8-K Shareholder Nominations Pursuant to Exchange Act Rule 14a-11  Interactive Data
08/03/2023 8-K Quarterly results
06/29/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Non-Reliance on Previous...
05/04/2023 8-K Quarterly results
03/30/2023 8-K Quarterly results
12/15/2022 8-K Quarterly results
11/01/2022 8-K Quarterly results
10/13/2022 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Letter re: Securities Registered under Registration Statement on Form S-3",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of October 13, 2022, between Axcella Health Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser a..."
09/29/2022 8-K Quarterly results
09/23/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "SECURITIES PURCHASE AGREEMENT",
"CONVERTIBLE PROMISSORY NOTE AXCELLA HEALTH INC. $[ ] New York, New York No. [ ] [ ] FOR VALUE RECEIVED, the undersigned, Axcella Health Inc., a Delaware corporation , hereby unconditionally promises to pay to [ ] or its registered assigns at the address specified in the Purchase Agreement in lawful money of the United States and in immediately available funds, the principal sum ofDOLLARS AND ZERO CENTS , together with interest as set forth in the Purchase Agreement until the date on which the principal amount is paid in full, converted in whole or cancelled in accordance with the terms of the Purchase Agreement. Amounts evidenced hereby shall be paid in the amounts and on the dates specified in Section 3 of the Purchase Agreement. This Note: is one of a series of similar Notes issued pursu..."
08/12/2022 8-K Quarterly results
08/02/2022 8-K Investor presentation
Docs: "Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID",
"NASDAQ: AXLA Axcella Therapeutics Phase 2A Long COVID Study Results Presentation Bill Hinshaw"
05/26/2022 8-K Quarterly results
05/25/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/30/2022 8-K Quarterly results
Docs: "Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update"
03/18/2022 8-K Termination of a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointmen...
03/16/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Letter re: Securities Registered under Registration Statement on Form S-3",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of March 16, 2022, between Axcella Health Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agr...",
"Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At the Market"
02/07/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement, by and between the Company and Robert Crane",
"Press Release issued by the Company on February 7, 2022, furnished hereto"
01/10/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "NASDAQ: AXLA Axcella Therapeutics Investor Presentation January 2022"
12/07/2021 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials"
09/07/2021 8-K Quarterly results
07/29/2021 8-K Quarterly results
Docs: "Axcella Reports Second Quarter Financial Results and Provides Business Update"
05/21/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
03/17/2021 8-K Quarterly results
03/03/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "Axcella Reports Third Quarter 2020 Financial Results and Provides Business Update"
08/31/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Releasees” and individually as a “Releasee”), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of set-off, demands and liabilities whatsoever of every name and nature, known or unknown, suspected or unsuspected, both at law and in equity, which Borrower, or any of its successors, assigns, or other legal representatives may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises at any time on or prior to the day and date of this Amendment, including, without limitation, for or on account o..."
08/05/2020 8-K Quarterly results
05/20/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/18/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Axcella Announces Pricing of Public Offering of Common Stock CAMBRIDGE, Mass. – May 13, 2020 – Axcella , a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators to pioneer a new approach for treating complex diseases and improving health, today announced the pricing of its underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $4.75 per share, before deducting underwriting discounts and commissions. In addition, Axcella has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other est...",
"Axcella Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option CAMBRIDGE, Mass. – May 18, 2020 – Axcella , a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators to pioneer a new approach for treating complex diseases and improving health, today announced the closing of its underwritten public offering of an aggregate of 12,650,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $4.75 per share, before deducting underwriting discounts and commissions. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Axcella, were approxi..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy